Sagimet Biosciences (SGMT) News Today $4.12 +0.09 (+2.23%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.13 +0.01 (+0.24%) As of 02/21/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from AnalystsSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have assigned a buyFebruary 21 at 6:21 AM | marketbeat.comSagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone SymposiumFebruary 19 at 8:48 AM | markets.businessinsider.comFY2024 Earnings Estimate for SGMT Issued By Leerink PartnrsSagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the comFebruary 10, 2025 | marketbeat.comBrokers Set Expectations for SGMT FY2029 EarningsSagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Sagimet Biosciences in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company wFebruary 7, 2025 | marketbeat.comSagimet Biosciences Inc. SGMT (U.S.: Nasdaq)February 2, 2025 | wsj.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives $23.00 Consensus PT from AnalystsSagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) has been given an average rating of "Moderate Buy" by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendatJanuary 29, 2025 | marketbeat.comSagimet Biosciences initiated with a Buy at JonesResearchJanuary 28, 2025 | markets.businessinsider.comJones Trading Initiates Coverage of Sagimet Biosciences (SGMT) with Buy RecommendationJanuary 28, 2025 | msn.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the cJanuary 26, 2025 | marketbeat.comPromising Potential of Denifanstat Drives Buy Rating for Sagimet BiosciencesJanuary 13, 2025 | markets.businessinsider.comSagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a bJanuary 1, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Stock, Insider Trading ActivityDecember 18, 2024 | benzinga.comAnalysts Offer Insights on Healthcare Companies: Chromadex (CDXC) and Sagimet Biosciences, Inc. Class A (SGMT)December 8, 2024 | markets.businessinsider.comOppenheimer Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform RecommendationDecember 7, 2024 | msn.comSagimet started at outperform by Oppenheimer, MASH drug citedDecember 7, 2024 | seekingalpha.comSagimet Biosciences (NASDAQ:SGMT) Now Covered by Analysts at OppenheimerOppenheimer began coverage on Sagimet Biosciences in a report on Friday. They set an "outperform" rating and a $30.00 target price on the stock.December 6, 2024 | marketbeat.comSagimet Biosciences price target lowered to $31 from $32 at JMP SecuritiesDecember 5, 2024 | markets.businessinsider.comSagimet Biosciences initiated with an Outperform at OppenheimerDecember 5, 2024 | markets.businessinsider.comSagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | finance.yahoo.comSagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | finance.yahoo.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from TD CowenNovember 22, 2024 | markets.businessinsider.comSagimet Biosciences participates ik,on NoNovember 20, 2024 | markets.businessinsider.comSagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024November 18, 2024 | markets.businessinsider.comSagimet Biosciences presents clinical denifanstat, preclinical FASN inhibitor daNovember 18, 2024 | markets.businessinsider.comPromising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program InitiationNovember 16, 2024 | markets.businessinsider.comSagimet Biosciences (NASDAQ:SGMT) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research report on Friday.November 15, 2024 | marketbeat.comSagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy RatingNovember 15, 2024 | markets.businessinsider.comSagimet Biosciences reports Q3 EPS (45c) vs (35c) last yearNovember 14, 2024 | markets.businessinsider.comSagimet: More Than Just A MASH Drug Development BiotechNovember 14, 2024 | seekingalpha.comSagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 14, 2024 | finance.yahoo.comSagimet draws buy at UBS on MASH opportunityNovember 13, 2024 | seekingalpha.comUBS Initiates Coverage of Sagimet Biosciences (SGMT) with Buy RecommendationNovember 13, 2024 | msn.comSagimet Biosciences: Promising Drug Denifanstat and Market Potential Drive Buy RatingNovember 12, 2024 | markets.businessinsider.comSagimet Biosciences initiated with a Buy at UBSNovember 12, 2024 | markets.businessinsider.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assignedNovember 12, 2024 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at UBS GroupUBS Group started coverage on Sagimet Biosciences in a research note on Tuesday. They issued a "buy" rating and a $12.00 price target on the stock.November 12, 2024 | marketbeat.comAscletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of AcneNovember 12, 2024 | prnewswire.comSagimet Biosciences to Participate in the UBS Global Healthcare ConferenceNovember 8, 2024 | markets.businessinsider.comSagimet’s denifanstat enters Phase III trials for MASH treatmentNovember 1, 2024 | msn.comSagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top AnalystOctober 31, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Sagimet Biosciences, Inc. Class A (SGMT), Boston Scientific (BSX)October 31, 2024 | markets.businessinsider.comSagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of Sagimet Biosciences in a research note on Thursday.October 31, 2024 | marketbeat.comSagimet Biosciences completes End-of-Phase 2 meeting with FDA on denifanstatOctober 30, 2024 | markets.businessinsider.comShort Interest in Sagimet Biosciences Inc. (NASDAQ:SGMT) Grows By 102.0%Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) was the recipient of a large growth in short interest in October. As of October 15th, there was short interest totalling 3,980,000 shares, a growth of 102.0% from the September 30th total of 1,970,000 shares. Approximately 18.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is presently 3.0 days.October 26, 2024 | marketbeat.comSagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate DenifanstatOctober 19, 2024 | seekingalpha.comSagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024October 16, 2024 | finance.yahoo.comSagimet Gains on Latest NumbersOctober 11, 2024 | baystreet.caSagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & HepatologyOctober 11, 2024 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC reduced its holdings in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) by 42.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,400 shares of the company's stoOctober 8, 2024 | marketbeat.comSagimet Biosciences’ Denifanstat Receives Buy Rating on FDA’s BTD and Promising Trial ResultsOctober 4, 2024 | markets.businessinsider.com Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMT Media Mentions By Week SGMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMT News Sentiment▼0.510.60▲Average Medical News Sentiment SGMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMT Articles This Week▼22▲SGMT Articles Average Week Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mineralys Therapeutics News Today Entrada Therapeutics News Today Cartesian Therapeutics News Today Humacyte News Today Arcturus Therapeutics News Today SNDL News Today KalVista Pharmaceuticals News Today ProKidney News Today ABIVAX Société Anonyme News Today Organogenesis News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
